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Summary 
The mechanism by which the mammalian mother accepts the implanting fetus as an allograft 
remains unexplained, but is likely to be the result of a combination of factors. Mononuclear cy- 
totrophoblasts, the specialized fetal cells of the placenta that invade the uterus, play an impor- 
tant role. These cells express HLA-G, an unusual major histocompatibility complex class I-B 
molecule,  and  secrete  cytokines and  pregnancy-specific proteins  that  can  regulate  immune 
function. We investigated whether cytotrophoblasts secrete interleukin 10 (IL-10), a cytokine 
that potently inhibits alloresponses in mixed lymphocyte reactions. Cytotrophoblasts from all 
stages of pregnancy produced IL-10 in vitro, but neither placental fibroblasts nor choriocarci- 
noma (malignant trophoblast)  cell lines did so.  Spontaneous IL-10 production averaged 650, 
853, and 992 pg/106 cells in the first,  second, and third trimesters of pregnancy, respectively. 
IL-10 secretion dropped ,',~10-fold  after the first 24 h  of culture, and was  paralleled by a de- 
crease in messenger tkNA. IL-10 messenger RNA was detected in biopsies of the placenta and 
the portion of the uterus that contains invasive cytotrophoblasts, suggesting that this cytokine is 
also produced in vivo. IL-10 secreted by cytotrophoblasts in vitro is bioactive, as determined 
by its ability to suppress  interferon ~/production in an allogeneic mixed lymphocyte reaction. 
We conclude that human cytotrophoblast IL-10 may be an important factor that contributes to 
maternal tolerance of the allogeneic fetus. 
D 
uring human pregnancy, genetically foreign cells from 
the  fetal  portion  of the  placenta  invade  the  uterus. 
This process is the result of differentiation of the specialized 
epithelial  cells  of the  placenta,  termed  trophoblasts  (re- 
viewed  in  1  and  2).  Mononuclear  cytotrophoblast stem 
cells are anchored to basement membranes surrounding the 
stromal  cores  of two  types  of chorionic villi.  In  floating 
villi,  cytotrophoblasts fuse  to  form  the  overlying syncy- 
tium, which is in direct contact with maternal blood, me- 
diating nutrient and gas exchange for the developing fetus. 
In anchoring villi,  cytotrophoblasts differentiate by leaving 
their basement  membrane  and  forming columns  of cells. 
These cell columns give rise to the invasive subpopulation 
of cytotrophoblasts that attaches to and invades the uterus 
and its arterial system. In response to cytotrophoblast inva- 
sion, the uterine stroma decidualizes and is infiltrated by a 
specific subset  of maternal immune  cells.  As  a result,  the 
pregnant human uterus contains a mixture of fetal and ma- 
ternal cells, the latter being up to 75% immune-competent 
bone marrow-derived cells (3). 
Because of their unique position at the maternal-fetal in- 
terface, placental trophoblast cells  are presumed  to  shield 
the allogeneic fetus from rejection (4, 5), although the mo- 
lecular mechanisms have not been fully defined. Faulk et al. 
(6, 7) suggested that the placenta passively evades immune 
recognition through the absence  of classical  class I  and  II 
MHC  antigens  on  syncytiotrophoblast  cells.  However, 
subsequent  studies  revealed that  invasive  cytotrophoblasts 
express a nonclassical class I antigen, HLA-G (8-10). It has 
been suggested that this molecule could function as a uni- 
versal  "self"-transplantation  antigen,  preventing  maternal 
imnmne attack of the feto-placental unit (9, 11). 
The localized secretion ofimmunomodulatory factors by 
the placenta may also contribute to survival of the fetal al- 
lograft. Hormones in high concentration at the placental- 
uterine  interface,  such  as  progesterone,  human  placental 
lactogen, prolactin, and estrogens, inhibit lymphocyte reac- 
tivity in vitro (12).  Other placental factors with inhibitory 
effects on immune function include  pregnancy-associated 
oL2-glycoprotein, pregnancy-associated plasma  protein  A, 
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hormones,  the  human  placenta secretes  a  variety of cyto- 
kines, including CSF-1 (14), M-CSF (15), IL-113 (16), IL-6 
(17,  18), and TGF-[3 (19, 20). 
Alloreactive T  lymphocyte responses are also suppressed 
by  other,  as yet undefined  substances  in  cytotrophoblast- 
conditioned  medium  (21)  and  in  the  supernatants  from 
cocultures of cyto- and syncytiotrophoblasts (22). This im- 
munosuppressive  activity is  very similar to  the  biological 
effects described for IL-10, an immunoregulatory cytokine 
that inhibits the generation of alloreactive T  cells in mixed 
lymphocyte reactions  (MLP,1;  23).  To  test  the  possibility 
that IL-10 may be involved in trophoblast-mediated mater- 
nal immune  inhibition, we investigated the production of 
IL-10 by several types of human  placental cells, including 
primary  cyto-  and  syncytiotrophoblasts,  placental  fibro- 
blasts,  and  choriocarcinoma  cell lines.  The  results  of this 
study show  that  IL-10 is produced specifically by primary 
cytotrophoblasts in vitro and that this cytokine can inhibit 
an allogeneic immune response. We hypothesize that IL-10 
may  play  an  important  role  in  suppressing  potentially 
harmful maternal immune responses in vivo. 
Materials  and Methods 
Placental Cell and Tissue Isolation and Culture.  Cytotrophoblasts 
were isolated from pooled first- or second- (24, 25) trimester and 
individual  third-trimester  (26)  human  placentas  by  published 
methods.  Chorionic viLli were  collected immediately after vac- 
uum aspiration and washed three times in wash medium (DME 
H-21,  2.5%  FCS,  1% peniciLlin/streptomycin). Placental fibro- 
blasts were isolated from first-trimester placentas as previously de- 
scribed (24).  The JAR  (27),  BeWo  (28),  and JEG  (29) human 
choriocarcinoma ceLl lines (American Type Culture Collection, 
Rockville, MD) were maintained as previously described (24). 
Cytotrophoblasts, choriocarcinoma cell lines,  and  fibroblasts 
(106) and chorionic villi (0.l g) were cultured in 1 ml of serum- 
free medium (DME H21 MEM containing 2% Nutridoma [Boeh- 
ringer Mannheim,  Indianapolis, IN]  and 50  I~g/ml gentimicin; 
serum-free medium)  in  16-mm  culture wells precoated with  a 
basement membrane substrate (Matrigel; Collaborative Research 
Inc.,  Bedford,  MA)  diluted two  parts  to  one  part  SFM as  de- 
scribed (25).  For immunohistochemical studies, cells were plated 
at a density of 2.5  ￿  10  s cells/ 500  ILl SFM in each well of an 
eight-well chamber  slide  (Nunc,  Inc.,  Naperville, IL).  PBMC 
were cultured in RPMI 1640 supplemented with 10% heat-inac- 
tivated human AB serum. 
Where specified, IL-10 production was stimulated by the addi- 
tion of 1 txg/ml LPS from Escherichia coli (Serotype No. 0127:B8; 
Sigma Immunochemicals, St. Louis, MO) to SFM. For metabolic 
labeling, 10  ~' cytotrophoblasts were cultured for 12 h in 1 ml cys- 
teine-  and  methionine-deficient  DME  containing  500  I~Ci 
Tran35S-label TM  (ICN Biomedicals Inc., Costa Mesa, CA). 
Quantification  of IL-10  in  Conditioned  Medium  (CM)  and  Cell 
Extracts.  CM was  collected after 24 h and centrifuged at 300 g 
for 8 rain. CM was then concentrated using Centriprep (5-15 ml 
I  Abbreviations used in this paper: CM,  conditioned medium; HPRT, hy- 
poxanthine-guanine phosphoribosyltransferase;  MLIK, nfixed lymphocyte 
reaction. 
medium) or Centricon (up to 3 m.l medium) concentrators with a 
10,000-mol wt cutoff (Amicon, Inc., Beverly, MA). Cell extracts 
were prepared by adding 1 ml lysis buffer (0.5% NP-40,  150 mM 
NaC1, 25 mM Tris-HC1, pH 7.5) containing 1 mM PMSF to the 
cultures. The resulting suspensions were passed  10 times through 
a 26-gauge needle. Lysates were then centrifuged at 16,000 g for 
5 rain to remove cellular debris and filtered through a 0.2-1*m fil- 
ter. CM and lysates were stored at -80~  IL-10 levels were de- 
termined by an ELISA developed in this laboratory as previously 
described (30-32). The sensitivity of the assay is 50 pg/nd. 
Immunocytochemistry.  Cells  cultured  overnight  in  chamber 
slides were fixed for 15 rain in acetone at -20~  then incubated 
in methanol containing 0.3% H202 for 10 nfin to block endoge- 
nous peroxidase activity. After a l-h incubation in antibody dilu- 
ent  (PBS  containing  0.7%  gelatin  from  cold-water  fish  skin; 
Sigma), a mixture of 25 I.~g/ml each of two mAbs to human IL-10 
(19Fl  [33] and  12G8  [31,  33])  was added for 48  h  at 4~  We 
were unable to detect IL-7 in cytotrophoblast conditioned me- 
dium by ELISA (data not shown).  Consequently,  as a  negative 
control, cytotrophoblasts were exposed to 50 txg/ml of a rat mAb 
to  human  IL-7  (BVD10-11C10;  33)  that was  of the same  IgG 
subclass as both  19F1  and  12G8.  As an additional control, cells 
were  exposed to antibody diluent alone.  Slides were  incubated 
with a  1:100  dilution of biotinylated goat anti-rat lgG  (Vector 
Laboratories, Inc., Burlingame, CA) for 60 rain at room tempera- 
ture. ABC reagent solution (Vector) was then added for 60 rain, 
and the peroxidase reaction was  developed by incubating with 
3,3'-diaminobenzidine  (Vector)  containing  NiC1.  Stained  cy- 
totrophoblasts were examined by bright-field optics with an Ax- 
iophot microscope (Carl Zeiss, lnc., Thornwood, NY) and pho- 
tographed with  Kodachrome  160  ASA tungsten  film  (Eastman 
Kodak Co., Rochester, NY). 
Immunoprecipitation.  106  metabolically labeled cells were  ex- 
tracted in 1 ml 2.5% Triton dilution buffer (TDB; 34) containing 
5 ~g/ml pepstatin, 10 I.~g/ml chymostatin, 5 I.Lg/ml leupeptin, 10 
l~g/ml antipain, 0.5 nM benzamidin, 0.5 U/ml trasylol, and 1 mM 
PMSF. CM (1 ml) was added to 0.5 ml TDB, and both medium 
and labeled cells were frozen at -80~  before use (1-7 d). Lysates 
and conditioned media were precleared twice with CL2-B beads 
(Pharmacia  LKB  Biotechnology,  Piscataway,  NJ)  as  described 
(35).  As an additional preclearing step, supernatants were added 
to 50 b~l of a 30%  (vol/vol) slurry of protein A-Sepharose (PAS) 
beads in PBS containing 0.03%  NaN  3 and incubated with a rat 
IgG2a mAb to ]3-galactosidase  (GLl17, I0 ~g/nfl) for 6 h at 4~ 
with continuous agitation. After 30 min, rabbit anti-rat IgG (10 
btg/rnl; Vector) was added to each tube. The precleared samples 
were  then  incubated  with  PAS  and  3.3  p,g/ml  each  of three 
n~_bs  to  human  1L-10  (12G8,  9D7  [3l],  and  19F1  [33])  with 
constant agitation for 12 h at 4~  Rabbit anti-rat IgG (10 ~g/ml; 
Vector) was added after 30 min. PAS beads were then pelleted by 
centrifugation and washed five times with mixed micelle buffer 
and three times with final wash buffer (FWB; 35), with a transfer 
of the beads to clean tubes during the second FWB wash.  Beads 
were boiled for 3 rain in Laemmli sample buffer containing 2.5% 
]3-mercaptoethanol and subjected to SDS-PAGE on a 15% acry- 
lamide gel. The gel was fixed for 10 min in glacial acetic acid, in- 
cubated for 1 h in EN3HANCE (DuPont Co., Wilmington, DE), 
rinsed twice in tap water, and incubated in HeO  containing 3% 
glycerol for 1 h  to precipitate the fluor. The gel was  then dried 
and exposed to X-OMAT A1K film (Kodak). 
Analysis of Cytotrophoblast IL-10 mRNA.  mRNA was extracted 
from  10  ~' cells  using RNAzol  TM  B  (Biotecx Laboratories, Inc., 
Houston,  TX)  according  to  the  manufacturer's  recommenda- 
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mia virus reverse transcriptase (GIBCO B1KL, Bethesda, MD) and 
random  hexamer  primers  (Sigma)  as  previously described  (36, 
37). To quantitate levels of IL-10 mRNA, cDNA was amplified 
in the presence of a multiple human cytokine competitor plasmid 
otherwise identical to a murine construct described in detail else- 
where  (36,  37).  Briefly, the  competitor plasmid, called DC10, 
consists  of  tandemly  arrayed  authentic  target  sequences  into 
which DNA spacers of 75-150  bp were introduced. Target se- 
quences in the competitor construct amplify with equivalent effi- 
ciency in  the  presence  of cDNA,  and  are  easily distinguished 
from the smaller wild-type amplimers by 2% agarose gel electro- 
phoresis and  ethidium bromide staining.  A  competitor for  the 
constitutively expressed gene, hypoxanthine-guanine phosphori- 
bosyltransferase (HPRT), was included in DC10,  allowing input 
cDNA to be standardized to comparable levels of HPRT expres- 
sion in each sample. 
The first step in quantitating IL-10 mtt.NA was to determine 
the amount ofHPP, T cDNA in each sample as a relative measure 
of total cDNA. In these initial PCR. reactions, equal volumes of 
DC10 were added to equal volumes of each of the cDNA sam- 
ples. The reaction products were separated by electrophoresis and 
visualized by  ethidium  bromide  staining.  Samples  containing 
large amounts of cDNA relative to DC10 resulted in a brighter 
wild-type band. Next, total cDNA levels were equalized among 
samples by adjusting the amounts of input cDNA while maintain- 
ing a  constant concentration of DC10.  In samples with a rela- 
tively high concentration of cDNA, a smaller volume was used in 
successive reactions until  the  ratio  of band  intensities between 
competitor and wild-type HPRT amplimers was identical in each 
sample.  To  determine  the  relative levels of IL-10  transcript in 
each sample, equal amounts of total cDNA, whose volumes were 
determined previously, were then used for amplification of IL-10. 
Competition for reagents between the  competitor, whose con- 
centration  remained  constant,  and  varying  amounts  of IL-10 
cDNA in each reaction resulted in different ratios of band intensi- 
ties.  As cDNA levels decreased, the larger competitor construct 
was preferentially amplified, resulting in a brighter band.  These 
relative amounts of wild-type and competitor reaction products 
provide a semiquantitative determination of relative levels of IL-10 
mP,  NA  in  each  sample.  Primer  sequences  were  as  follows: 
HPRT  3':  CCTGCTGGATTACATCAAAGCACTG;  HPI<T 
5': TCCAACACTTCGTGGGGTCCT;  IL-10 3': ATGCCC- 
CAAGCTGAGAACCAAGACCCAGAC; IL-10 5': TCTCAA- 
GGGGCTGGGTCAGCTATCCCA. 
PCR of Placental Biopsies.  Total R.NA was isolated from fro- 
zen, pulverized biopsies of term placenta and placental bed by us- 
ing P,  NAzol  TM  B  (Biotecx Laboratories, Inc., Houston, TX) ac- 
cording  to  the  manufacturer's  recommendations  and  reverse 
transcribed as described above. IL-10 cDNA was amplified using 
primers shown above. 
MLR.  PBMC  were  prepared  by  centrifugation  of blood 
from normal donors on a Ficoll-Hypaque 1077  (Sigma)  density 
gradient according to  the  manufacturer's recommendation.  10  s 
PBMC  (responders) were mixed with  105 irradiated (3,000  rad) 
allogeneic  PBMC  (stimulators)  and  cultured  in  triplicate  in 
round-bottom  microtiter plates  (200  I,d/weU).  In  some  wells, 
CM  from  individual preparations  of cytotrophoblast cells  was 
added at a final concentration of 50% (vol/vol). Where specified, 
CM  was preabsorbed with  20-0.15  Izg/ml of a  function-per- 
turbing antibody to IL-10 (anti-lL-10, 19F1;  23, 38)  or an anti- 
[3-galactosidase  antibody matched for IgG subclass  (control IgG, 
GLl17; 31)  for 3 h at 37~  before addition. On day 5,  the me- 
dium  was  harvested and  centrifuged for  10  rain  at  300 g.  An 
ELISA specific for IFN-"/, developed in this laboratory (32), was 
performed to determine levels of this cytokine in the culture me- 
dium. The sensitivity of the assay is 50 pg/ml. Data were analyzed 
using the Mann-Whitney U test for nonparametric distribution. 
Results 
Human  Placental  Cytotrophoblasts  Secrete IL-IO  In  Vitro. 
We  first examined  cytokine synthesis by a  variety of pla- 
cental cells, using ELISA. To test cytotrophoblast produc- 
tion  of cytokines,  we  used  an  in  vitro  system  shown  by 
stage-specific antigen expression (reviewed in  1  and 2)  to 
model the  differentiation of these  cells along the  invasive 
pathway in vivo.  To  obtain the required number  of cells, 
first-trimester  cytotrophoblasts  were  isolated  from  5-10 
pooled placentas (n  =  16), second-trimester cells from  1-4 
pooled placentas (n =  14), and term cells from a single pla- 
centa (n =  8). Cytotrophoblast populations prepared in this 
way are 95% free of CD-45-positive immune  cells, them- 
selves potential cytokine-producing contaminants (25). We 
also analyzed CM  from  organ cultures of intact chorionic 
villi. Under these  conditions, syncytiotrophoblasts are the 
primary source of secreted molecules. Cytokine production 
by other placental cell types,  including first-trimester pla- 
cental fibroblasts and the BeWo, JAR, and JEG choriocar- 
cinoma cells lines, was also investigated. 
We recently showed that purified cytotrophoblasts pro- 
duce IL-113, with highest levels secreted during the first tri- 
mester of pregnancy  (16).  In the present experiments, we 
confirmed  previous  reports  that  these  cells produce  IL-6, 
but neither IL-2, -3, -4,  -5,  -7, nor IFN-'y were  detected 
by ELISA in CM  (data not shown). In contrast, all cultures 
contained IL-10 in levels that were  >50 pg/ml, the mini- 
mum sensitivity of the assay (Fig. 1). There were no signif- 
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Figure  1.  IL-10 levels secreted by cultured human  cytotrophoblasts. 
Cytotrophoblasts were isolated from pooled first or second trimester (TM) 
or individual term human placentas. 106 cells were cultured in 1 ml se- 
rum-free medium. After 24 h, CM was collected, and levels of secreted 
IL-10 were quantified by ELISA. Each point represents the level of IL-10 
in the CM of one preparation of cytotrophoblast cells. Diamonds signify 
means with 95% confidence intervals. 
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totrophoblasts  from  different  gestational  ages.  However, 
there were substantial differences in the absolute amount of 
IL-10 secreted by cells obtained from different pregnancies. 
Human immune cells secrete IL-10 in vitro after activation 
with agents such as endotoxin (30).  Although cytotropho- 
blasts secreted IL-10 without stimulation, addition ofl  p~g/ml 
LPS  to  first-trimester  cells  increased  IL-10  secretion  ap- 
proximately threefold compared to untreated cells from the 
same preparation. With regard to other placental cell types, 
0.1  g  of chorionic villi produced ~2  ng IL-6, but less than 
50 pg of IL-10, suggesting that syncytiotrophoblasts do not 
produce  considerable quantities  of the  latter cytokine.  In 
addition, neither the CM nor lysates of placental fibroblasts 
or choriocarcinoma cells contained IL-10. These data sug- 
gest that cytotrophoblasts are the major placental source of 
IL-10  in  vitro  and  that  the  choriocarcinoma cell lines  do 
not secrete this cytokine. 
We  used  a  second experimental approach to verify that 
human  cytotrophoblasts  synthesize  IL-10.  Purified  cells 
were cultured for 12 h  and immunostained with mAbs spe- 
cific for IL-10. An mAb to IL-7 that was matched for IgG 
subtype  was  used  as  a  control.  Purified  cytotrophoblasts 
form aggregates during the first 48 h  of culture when plated 
at  subconfluent  levels  (25).  A  subset  of such  cells reacted 
with  IL-10 antibodies (Fig.  2  A), but  not with  IL-7 anti- 
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Figure  2.  lmmunodetection  of 1L-II) in 
cultured human cytotrophoblasts. 2.5  ￿  105 
first-trimester cytotrophoblasts were cultured 
in 500 pA serum-free medium. After 12 h, cells 
were fixed and stained with  mAbs to  IL-10 
(A) or IL-7 (B), as described in Materials and 
Methods. Bar, 100 p~rn; inset bar, 10 ~m. bodies (Fig. 2  B). In accordance with the ELISA data, pla- 
cental fibroblasts and the choriocarcinoma cell lines did not 
stain positively for IL-10. 
Temporal Regulation  of lL- l O Production.  To  establish that 
cytotrophoblasts produce, as well as secrete, IL-10 in vitro, 
we  imrnunoprecipitated this protein from lysates and  CM 
prepared from metabolically radiolabeled cells (Fig. 3). Au- 
toradiography of the  electrophoretically separated  imrnu- 
noprecipitates showed  a  single band  corresponding to  the 
molecular mass  of human  IL-10  (18  kD).  This  band  was 
most prominent in CM  collected from cells that had been 
cultured for 12 h, and it decreased in intensity over the 60-h 
culture period. Cell lysates contained much lower, but still 
detectable  levels  of IL-10,  and  again  the  highest  amount 
was seen after 12  h  in culture.  No specific bands were de- 
tected in immunoprecipitates obtained using an antibody to 
IL-7  (25  kD).  These  results  suggest  that  cytotrophoblast 
synthesis of IL-10 is highest during the first 12  h,  and that 
this cytokine is rapidly secreted into the medium. This was 
verified by ELISA, which showed that the amount oflL-10 
secreted by cytotrophoblasts dropped  after  24  h  to  levels 
that  were  below  the  sensitivity of the  assay.  During  this 
same period, cytotrophoblast cells cultured under identical 
conditions remain viable as indicated by their continued se- 
cretion of placental hormones  (e.g., human  chorionic go- 
nadotropin;  24)  and by their expression of newly synthe- 
sized stage-specific antigens (reviewed in 1 and 2). 
Mechanism of Downregulation  of lL-lO Synthesis.  To  elu- 
cidate the mechanism by which protein synthesis is down- 
regulated, we used a competitive PCR-based method with 
primers specific for human IL-10 to measure mR.NA levels 
in cultured cells. We were unable to detect message for this 
cytokine  in  samples from  control  cultures  of placental fi- 
broblasts  or  the  BeWo, JAR,  and JEG  cell  lines.  IL-10 
message was,  however,  readily detected in first-, second-, 
and  third-trimester  cytotrophoblasts  (Fig.  4)  both  at  the 
time  of isolation (time 0)  and after as long as 2  d  in vitro 
(48  h).  In  accordance  with  the  imrnunoprecipitation  and 
ELISA data, the amount oflL-10 mRNA  (as normalized to 
HPla.T)  decreased  with  time  in  culture.  Together,  these 
data suggest that the decline in IL-10 production in vitro is 
transcriptionally regulated. 
The  presence of IL-10 mP,  NA in  cytotrophoblasts im- 
mediately after purification suggests  that  these  cells either 
synthesize IL-10 in vivo or are induced to do so by the iso- 
lation  procedure.  To  begin  to  address  this  question,  we 
used RT-PCR.  to  analyze various tissues that  are  compo- 
nents  of the  maternal-fetal interface.  Both  chorionic  villi 
and the portion of the uterus to  which  anchoring villi at- 
tach expressed IL-10 rnRNA (data not shown).  Since these 
specimens contain a variety of cell types in addition to cy- 
totrophoblasts, it remains to be determined which of these 
cells produce IL-10 in vivo. 
Cytotrophoblast  IL-10 is Immunoinhibitory.  Next,  we  in- 
vestigated whether it was possible to  detect one biological 
activity of IL-10, namely the ability to inhibit an allogeneic 
immune  response, within  the complex mixture  of growth 
factors and cytokines that cytotrophoblasts secrete. Specifi- 
cally, we measured the ability ofcytotrophoblast CM to in- 
hibit  IFN-y  production  in  an  MLR.  In  control  experi- 
ments, the addition of 1-100 U  rlL-10 to an MLP, inhibited 
IFN-~/secretion in a dose-dependent manner. As previously 
shown, as little as 1 U  rlL-10 was su~cient to reduce IFN-~/ 
Figure 3.  Human cytotrophoblasts  synthesize IL-10 in vitro. Term cy- 
totrophoblasts were metabolically  labeled for 12 h beginning at 0, 24, and 
48 h in culture. CM was collected, and a cell extract (EX) was prepared. 
Samples were incubated overnight with mAbs to IL-10 or, as a negative 
control, an mAb to IL-7. The resulting immune complexes were sepa- 
rated on a 15% polyacrylamide gel and exposed to film for 3 d. 
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Figure 4.  Relative levels oflL-10 mRNA in human placental cytotro- 
phoblasts over time in culture. Placental cytotrophoblasts were isolated as 
described in Materials and Methods from pooled first or second trimester 
(TM) or individual term placentas, and 1LNA was extracted and reverse 
transcribed, cDNA was amplified by PCR. in the presence of the compet- 
itor plasmid, DC10  (see Materials and Methods), allowing the  relative 
levels of IL-10  mRNA  to  be  quantified  by  comparing  the  relative 
amounts of  the larger competitor sequence (upper  band in each lane) and the 
wild-type transcript (lower  band in each lane). The equal relative intensities 
of cDNA and competitor HPRT amplimers in each sample (upper  panel) 
indicate that an equal amount of  input cDNA was added to each reaction. 
IL-10 transcripts  were then quantitated by using these equalized amounts 
of input cDNA in PCIL reactions containing a constant amount of DC10 
(lower  panel). Over the course of this experiment (48 h), the larger com- 
petitor  construct became preferentially amplified, indicating that  IL-10 
mfLNA levels decreased in cytotrophoblasts of all gestational ages with 
time in culture. Results are representative of two experiments. IL-IO 
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Figure  5.  IL-10 in cytotrophoblast CM inhibits IFN-y secretion in a 
primary MLR. Cytotrophoblast CM (CTB CM) was collected after 12 h 
from individual preparations of cells, and absolute amounts of IL-10 in 
each sample were determined by ELISA. AUoreactive  lymphocytes were 
cultured in triplicate as described in Materials and Methods in the pres- 
ence of RPM1 alone (white bar) or 50% (vol/vol) CTB CM from individ- 
ual cell preparations either untreated (black bars) or preabsorbed with  I0 
Dg/ml of a neutralizing mAb to IL-10 (hatched bars). After 5 d, CM was 
collected and  IFN-'y levels in  triplicate cultures were  determined  by 
ELISA. Data of all experiments are presented as mean +  SEM. Asterisks 
denote significant increases in IFN-',/ secretion (P <0.05 by the Mann- 
Whitney U test for nonparametric distribution). 
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Figure 6.  Dose-response inhibition of IFN-y secretion by cytotropho- 
blast IL-IO, CM was collected from cytotrophoblast cells  after 12 h in cul- 
ture. Alloreactive lymphocytes were cultured in triplicate as described in 
Materials and Methods in the presence of 50% (vol/vol) CM or 1,000 
pg/ml rlL-10, each preabsorbed with 20 to 0.15 btg/ml of a neutralizing 
mAb to  IL-10 (anti-IL-10; A) or an isotype-matched control antibody 
(control IgG;/3). Results shown are from two individual experiments and 
represent mean -+ SEM. [], 1,000 pg/ml rlL-10; [], CTB CM. 
levels  by  ~-'25%,  and  the  function-perturbing  antibody 
19F1  reversed  this  suppressive  activity  (23).  In  addition, 
19F1  increased basal IFN-~/ levels by neutralizing endoge- 
nous  IL-10 when  added alone  to  an  MLR.  These  effects 
were  not  observed  when  a  nonspecific  antibody  of the 
same IgG subtype was  used as a  control.  Addition of CM 
from different preparations of cytotrophoblasts to an MLR 
had  variable effects on  IFN-y production  (Fig.  5).  How- 
ever, neutralizing IL-10 in cytotrophoblast CM resulted in 
a  significant increase in  IFN-~/ secretion in many  samples 
(n =  8, P  <0.05).  In these experiments, the ability to stim- 
ulate  tFN-y  production  positively  correlated  with  the 
amount  of IL-10 in the CM  (correlation coefficient i  2 = 
0.86).  Titrating 19F1  in the CM of one preparation of cy- 
totrophoblasts  resulted  in  a  dose-response  stinmlation  of 
IFN-y production  (Fig. 6  A). Again, the isotype-matched 
control  antibody had  no  effect  (Fig.  6  B).  These  observa- 
tions show  that  IL-10 secreted by cytotrophohlasts acts  to 
inhibit allogeneic lymphocyte reactivity in vitro. 
Discussion 
We report that IL-10 secreted by highly purified human 
placental cytotrophoblasts can  suppress  an  allogeneic im- 
mune  response in vitro. Human  IL-10 is a pleiotropic cy- 
tokine that is produced by activated immune  cells includ- 
ing human  CD4 + T  cell clones (Th0,  Thl,  and Th2  cells; 
39),  B  cells  (40),  and  monocytes  (30),  by  UV-irradiated 
murine keratinocytes (41), and by a variety of human carci- 
noma cell lines (38). Among its activities, IL-10 suppresses 
both  T  cell proliferative responses and  IFN-y production 
in MLP,.s when allogeneic cells are used as stimulators (23). 
IL-10 suppresses alloresponses by inhibiting the expression 
of both  MHC  class  II  molecules  and  the  costimulatory 
molecule B7  (42,  43).  Alloreactive T  ceils, such  as  those 
generated in these reactions, play a key role in allograft re- 
jection  (44).  These  effects  of IL-10  make  it  an  attractive 
candidate for suppressing transplant rejection and prolong- 
ing graft survival (45). 
To investigate the possibility that IL-10 may be involved 
in  protecting  the  allogeneic  fetal  "transplant"  in  human 
pregnancy, we  determined whether placental cells synthe- 
size this cytokine. Of the cells we studied, only primary cy- 
totrophoblasts  secreted  IL-10  in  vitro,  in  levels  ranging 
from  67  to  2,190  pg/ml  during the  first 24  h  of culture. 
Our  findings  correlate  with  IL-10  production  in  several 
human  diseases,  in  which  systemic  cytokine  levels  are 
equally variable. For example, serum levels of IL-10 in pa- 
tients with meningococcal septic shock (46) or diffuse large 
cell lymphoma (47) range from 25 to 64,500 pg/ml and ~<5 
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of mice injected with an antibody to CD3 displays a nine- 
fold variation in serum concentrations of IL-10 (48).  The 
intersample variability of IL-10 production by cytotropho- 
blasts  is  also  reflective of the  biologic variation  in  preg- 
nancy-specific hormone production by different placentas. 
For  example,  the  amount  of human  placental  lactogen 
(hPL) released by cultured placentas covers a fivefold range 
of values (49). This is also observed in vivo, where circulat- 
ing levels ofhPL in normal pregnancy range from 3.3 to 25 
~g/ml in the third trimester (50).  As  each placenta is the 
product of a unique immune and hormonal environment, 
it follows that  the  production of IL-10 will be  regulated 
differently in each pregnancy. 
Purified cytotrophoblasts contain IL-10 mRNA  imme- 
diately after the isolation procedure, before culture. Both 
IL-10 gene transcription and subsequent protein secretion 
drop within 24 h  in vitro. During this time,  cytotropho- 
blasts are actively differentiating as they do during uterine 
invasion in  vivo; they modulate  the  expression of mole- 
cules whose functions mediate either maternal immune tol- 
erance  (e.g.,  HLA-G;  10)  or invasion  (e.g.,  integrin cell- 
ECM receptors [51] and MMP-9 [24]). We have evidence 
that  IL-10  can  affect both  of these  important  functions. 
With  regard  to  immune  aspects  of pregnancy,  we  show 
here that IL-10 in cytotrophoblast CM inhibits alloreactiv- 
ity.  In addition, preliminary data suggest that endogenous 
IL-10 downregnlates the production of MMP-9,  which is 
required for invasion in vitro (25). 
It has been suggested that the maternal immune system 
in pregnancy is biased towards antibody production, while 
harmful  cell-mediated  immunity  is  weakened  (52).  The 
generation  of a  humoral  response  is  associated  with  the 
production of Th2-type cytokines,  including  IL-3,  IL-4, 
IL-5,  IL-10,  and  IL-13.  Of these,  IL-10  directly inhibits 
synthesis  of proinflammatory  Thl-type  cytokines  (e.g., 
IFN-'y), thus preventing the development of cytotoxic im- 
mune cells (39,  53). Several groups have demonstrated the 
production  of Th2  cytokines by tissues  at  the  maternal- 
fetal interface in nmrine gestation (54,  55).  However, the 
precise identity of the cell types producing these cytokines 
has not been elucidated. This report shows that in human 
pregnancy, cytotrophoblasts secrete IL-10. Consistent with 
the  ability  of IL-10  to  inhibit  the  production  of Thl 
cytokines, we did not detect IFN-',/in purified cytotropho- 
blasts  by any of several methods  used  (56).  We  postulate 
that  the  localized  production  of IL-10  by  the  placenta 
serves  to protect the human fetus by driving the maternal 
immune  system away from a  potentially deleterious cell- 
mediated Thl response. 
For  IL-10  to  function  as  a  local  immunoinhibitor  in 
pregnancy, its levels within the uterine wall must be suffi- 
cient  to  suppress  a  harmful  maternal  immune  response. 
Since 100 pg/ml rlL-10 is sufficient to inhibit T  cell prolif- 
eration in an MLR. (23),  the amount of IL-10 secreted by 
these cells in vitro is in a physiologically relevant range. In 
addition, we and others have detected IL-10 mR.NA in bi- 
opsies of both placenta (57) and placental bed, the decidu- 
alized  uterine  tissue  into  which  cytotrophoblasts invade. 
IL-10 has also been demonstrated to be present in human 
amniotic  fluid  (58).  Together,  these  observations suggest 
that this cytokine could be produced in sufficient amounts 
to be active in vivo. We have also shown that cytotropho- 
blast-derived IL-10 is immunosuppressive in vitro, as deter- 
mined by its  effect on IFN-y secretion in an MLR.  The 
fact that we detected this activity in the  complex growth 
factor and  cytokine  mixture  in  CM  suggests  that  IL-10 
could play an  important  role in  maintaining  the  fetal al- 
lograft. 
The significance of placental IL-10 production in vivo is 
difficult to assess in animal models because many aspects  of 
human pregnancy are unique. For example, human mono- 
nuclear cytotrophoblasts behave like tumor cells in that they 
migrate deep into the uterine wall, mixing extensively with 
maternal decidual cells  (2).  Mouse placentation is  charac- 
terized  by  shallow  invasion  by  multinucleate  giant  cells, 
which results  in the formation of a distinct fetal-maternal 
boundary  (2).  Human pregnancy is  also  immunologically 
unique, as evidenced by the fact that invasive cytotropho- 
blasts  express  HLA-G  (8-10).  It  is  not  known  whether 
there is a mouse HLA-G homologue. In addition, the sub- 
stantial  difference in the length of gestation in the two spe- 
cies  (20 d in the mouse vs. 40 wk in the human)  suggests 
that  different  immunomodulatory  mechanisms  might  be 
required for protection of the allogeneic fetus. Therefore, 
the successful  birth of IL-10-deficient mice  (59)  does not 
exclude the  possibility that this  cytokine is  important for 
the maintenance of human pregnancy. In fact, recent evi- 
dence  suggests  that  IL-10  production  is  disregulated  in 
some  reproductive  pathologies.  IL-10  levels  are  signifi- 
cantly  elevated  in  the  amniotic  fluid  of small-for-gesta- 
tional-age  pregnancies,  these  being  the  leading  cause  of 
perinatal morbidity and mortality (58). Additionally, PBMCs 
isolated from women suffering from recurrent spontaneous 
abortions were found to secrete the Thl cytokines IFN-',/, 
IL-2, TNF-]3, and TNF-e~ when stimulated with tropho- 
blast  antigens in vitro (60).  In contrast, the supernatant of 
PBMCs  from  reproductively  normal  women  contained 
IL-10,  with  undetectable  levels  of Thl  cytokines.  These 
observations of human pregnancy suggest that IL-10 may 
be an important factor for a healthy, term gestation. 
The observed maternal immune tolerance of the geneti- 
cally foreign fetus in mammalian pregnancy is  a complex 
phenomenon.  Undoubtedly, multiple mechanisms are in- 
volved in preventing immune rejection of the feto-placen- 
tal unit. The expression of HLA-G by invasive cytotropho- 
blasts is one way by which the human placenta can shield 
the conceptus from an immune attack.  In addition to this 
evasive mechanism, the localized secretion of immunoreg- 
ulatory cytokines may be very important in dampening an 
inflammatory immune response. In light of this evidence, it 
is tempting to speculate that cytotrophoblast-derived IL-10 
plays a key role in protecting the allogeneic human fetus in 
pregnancy. 
545  Roth et al. This work was  supported by grants  from the  National Institutes of Health  (HD  26732,  HD  30367,  AI 
26918,  and HL 07185).  The DNAX Research Institute is entirely supported by the Schering-Plough Cor- 
poration. 
Address correspondence to Susan J. Fisher, HSW 604, University of California at San Francisco,  San Fran- 
cisco, CA 94143-0512. 
Received for publication  28 March  1996 and in revised form 3June  1996. 
References 
1.  Damsky, C., A. Sutherland, and S. Fisher. 1993. Extracellular 
matrix 5: adhesive interactions in early mammalian embryo- 
genesis, implantation,  and  placentation.  FASEB  (Fed. Exp. 
Soc. Exp. Biol.)J.  7:1320-1329. 
2.  Cross, J.C., Z. Werb, and S.J. Fisher. 1994.  Implantation and 
the placenta: key pieces of the  development puzzle. Science 
(Wash.  DC). 266:1508-1518. 
3.  Starkey, P.M.,  I.L. Sargent, and C.W.  Redman.  1988.  Cell 
populations in human early pregnancy decidua: characteriza- 
tion and isolation of large granular lymphocytes by flow cy- 
tometry. Immunology. 65:129-134. 
4.  Beer, A.E., andJ.O. Sio. 1982. Placenta as an immunological 
barrier. Biol. Reprod. 26:15-27. 
5.  Sionov,  R.V.,  S.  Yagel,  N.R.  Har,  and  R.  Gallily. 1993. 
Trophoblasts protect  the  inner  cell mass  from  macrophage 
destruction. Biol. Reprocl. 49:588-595. 
6.  Faulk, W.P., and A. Temple. 1976. Distribution of beta2 mi- 
croglobulin and HLA in chorionic villi of human placentae. 
Nature (Lond.). 262:799-802. 
7.  Faulk, W.P., A.R. Sanderson, and A. Temple.  1977.  Distri- 
bution of MHC antigens in human placental chorionic villi. 
Transplant Proc. 9:1379-1384. 
8.  Ellis, S.A., I.L. Sargent, C.W. Redman, and A.J. McMichael. 
1986.  Evidence for a novel HLA antigen found on human 
extravillous trophoblast and a choriocarcinoma cell line. Im- 
munology. 59:595-601. 
9.  Kovats,  S.,  E.K.  Main,  C.  Librach,  M.  Stubblebine,  S.J. 
Fisher, and R. DeMars. 1990.  A class I antigen, HLA-G, ex- 
pressed  in  human  trophoblasts.  Science (Wash.  DC).  248: 
220-223. 
10. McMaster,  M.T.,  C.L.  Librach, Y.  Zhou,  K.H.  Lim,  M.J, 
Janatpour, R. DeMars, S. Kovats, C. Damsky, and S.J. Fisher. 
1995.  Human  placental HLA-G  expression is  restricted to 
differentiated cytotrophoblasts.J. Immunol.  154:3771-3778. 
11. Redman,  C.W.  1990.  Are there immunologically mediated 
abortions? If so, which mechanisms? Res. Immunol. 141:169-175. 
12. Siiteri, P.K., and D.P. Stites. 1982.  Immunologic and endo- 
crine interrelationships in pregnancy. Biol. Reprod. 26:1-14. 
13. Rocklin, R.E.,J.L. Kitzmiller, and M.D. Kaye. 1979.  Immu- 
nobiology of the maternal-fetal relationship. Annu. Rev. Med. 
30:375-404. 
14. Kauma, S.W., S.L.  Aukerman, D. Eierman, and T.  Turner. 
199l.  Colony-stimulating factor-1  and  c-fins expression in 
human endometrial tissues and placenta during the menstrual 
cycle and  early pregnancy. J.  Clin.  Endocrinol. Metabol.  73: 
746-751. 
15. Saito, S., K. Motoyoshi, M. Saito, Y. Kato, M. Enomoto, K. 
Nishikawa, T. Morii, and M.  Ichijo. 1993.  Localization and 
production of human  macrophage colony-stinmlating factor 
(hM-CSF) in human placental and decidual tissues. Lympho- 
kine Cytokine Res.  12:101-107. 
16. Librach, C.L., S.L. Feigenbaum, K.E. Bass, T.Y. Cui, N. Ve- 
rastas,  Y.  Sadovsky, J.P.  Quigley,  D.L.  French,  and  S.J. 
Fisher. 1994.  Interleukin-1 beta regulates human cytotropho- 
blast metalloproteinase activity and invasion in vitro. J.  Biol. 
Chem.  269:17125-17131. 
17. Kameda, T.,  N.  Matsuzaki, K. Sawai, T.  Okada, F.  Saji, T. 
Matsuda, T. Hirano, T. Kishimoto, and O. Tanizawa.  1990. 
Production  of interleukin-6 by normal human  trophoblast. 
Placenta. 11:205-213. 
18. Nishino,  E.,  N.  Matsuzaki,  K.  Masuhiro,  T.  Kameda,  T. 
Taniguchi, T. Takagi, F. Saji, and O. Tanizawa.  1990.  Tro- 
phoblast-derived interleukin-6 (IL-6) regulates human chori- 
onic gonadotropin release  through IL-6 receptor on human 
trophoblasts.J. Clin. Endocrinol. Metabol. 71:436-441. 
19. Kauma, S., D. Matt, S. Strom, D. Eierman, and T. Turner. 
1990.  Interleukin-1 beta, human leukocyte antigen HLA-DR 
alpha, and transforming growth factor-beta expression in en- 
dometrium, placenta, and placental membranes. Am..l.  Obstet. 
Gynecol. 163:1430-1437. 
20.  Dungy, L.J., T.A. Siddiqi, and S. Khan.  199l. Transfomfing 
growth  factor-beta  1  expression during  placental develop- 
ment. Am.J.  Obstet. Gynecol. 165:1853-1856. 
21. Silver, R.K., J.M. Turbov, J.A. Beaird, and J, Golbus. 199(t. 
Soluble factors produced by isolated first-trimester chorionic 
villi directly inhibit proliferation ofT cells. An1.J.  Obstet. Gy- 
necol. 163:1914-1919. 
22.  Sanyal, M.K., C.J. Brami, P. Bischof, E. Simmons, E.R. Bar- 
nea, J.M.  Dwyer, and F. Naftolin. 1989.  Immunoregulatory 
activity in supernatants from cultures of normal human  tro- 
phoblast cells  of the  first  trimester. Am. J.  Obstet. Gynecol. 
161:446-453. 
23. Bejarano, M.T., R. de Waal Malefyt, J.S. Abrams, M. Bigler, 
R. Bacchetta, J. de Vries, and M.G. Roncarolo. 1992.  Inter- 
leukin 10 inhibits allogeneic proliferative and cytotoxic T cell 
responses generated in primary mixed lymphocyte cultures. 
hit.  Immunol. 4:1389-1397. 
24.  Fisher, S.J., T.Y. Cui, L. Zhang, L. Hamnan, K. Grahl, G.Y. 
Zhang, J.  Tarpey,  and  C.H.  l)amsky.  1989.  Adhesive and 
degradative  properties  of human  placental  cytotrophoblast 
cells in vitro._/.  Cell Biol. 109:891-902. 
25.  Librach,  C.L.,  Z.  Werb,  M.L.  Fitzgerald, K.  Chiu,  N.M. 
Corwin, R.A. Esteves, D. Grobelny, R. Galardy, C.H. l)am- 
sky, and S.J. Fisher. 1991.  92-kD type IV collagenase inedi- 
546  Placental Interleukin 10 Is lmmunosuppressive ates  invasion of human  cytotrophoblasts. J.  Cell  Biol. 113: 
437-449. 
26. Kliman, H.J., J.E.  Nestler, E.  Sermasi, J.M.  Sanger, and J.F. 
Strauss  III.  1986.  Purification, characterization, and in vitro 
differentiation of cytotrophoblasts from human term placen- 
tae. Endocrinology. 118:1567-1582. 
27. Pattillo, R.A., A.C. Ruckert, R.O. Hussa, R. Bernstein, and 
E. Delfs. 1971.  The JAR cell line: continuous human multi- 
hormone production and controls. In Vitro. 6:398-405. 
28.  Pattillo, R.A., and G.O.  Gey.  1968.  The establishment of a 
cell line of human  hormone-synthesizing trophoblastic cells 
in vitro. Cancer Res. 28:1231-1236. 
29. Kohler,  P.O.,  and  W.E.  Bridson.  1971.  Isolation of hor- 
mone-producing clonal lines of human  choriocarcinoma. J. 
Clin.  Endocrinol. Metabol. 32:683-687. 
30. de Waal Male@t, R., J.  Abrams, B.  Bennett,  C.G.  Figdor, 
andJ. de Vries. 1991.  Interleukin 10 (IL-10) inhibits cytokine 
synthesis by human monocytes: an autoregulatory role of IL-10 
produced by monocytes.J. Exp. Med.  174:1209-1220. 
31. Abrams, J.S., M.G. Roncarolo, H. Yssel, U. Andersson, GJ. 
Gleich,  and J.E.  Silver.  1992.  Strategies  of anti-cytokine 
monoclonal  antibody development:  immunoassay  of IL-10 
and IL-5 in clinical samples.  Immunol.  Rev.  127:5-24. 
32. Abrams, J.S.  1995.  Immunoenzymetric  assay of mouse  and 
human cytokines using NIP-labeled anti-cytokine antibodies. 
/n  Current  Protocols  in  Immunology. J.E.  Coligan,  A.M. 
Kruisbeek, D.H. Margulies, E.M.  Shevach, and W. Strober, 
editors. John Wiley & Sons, New York. Unit 6.20. 
33. Andersson, J., S. Nagy, L. Bjork, J. Abrams, S. Holm, and U. 
Andersson.  1992.  Bacterial toxin-induced cytokine produc- 
tion studied at the single-cell level. Immunol. Rev. 127:69-96. 
34. Casanova, J.E., G. Apodaca, and K.E. Mostov. 1991.  An au- 
tonomous signal for basolateral sorting in the cytoplasmic do- 
main of the  polymeric immunogtobutin  receptor.  Celt.  66: 
65-75. 
35. Breitfeld, P.P., J.E. Casanova, J.M. Hams, N.E. Simister, and 
K.E. Mostov. 1989.  Expression and analysis of the polymeric 
immunoglobulin  receptor  in  Madin-Darby  canine  kidney 
cells using retroviral vectors. Methods Cell Biol. 32:329-337. 
36.  Reiner,  S.L.,  S.  Zheng,  D.B.  Corry,  and  R.M.  Locksley. 
1993.  Constructing polycompetitor cDNAs for quantitative 
PCR. J. Immunol.  Methods. 165:37-46. 
37. Corry,  D.B.,  H.G.  Folkesson,  M.L.  Warnock,  DJ.  Erle, 
M.A. Matthay, KJ.  Wiener, and R.M.  Locksley. 1996.  In- 
terleukin 4,  but not interleukin 5 or eosinophils, is required 
in a murine model of acute airway hyperreactivity [see com- 
ments].J. Exp. Med.  183:109-117. 
38.  Gastl,  G.A., J.S.  Abrams,  D.M.  Nanus,  R.  Oosterkamp, J. 
Silver,  F.  Liu,  M.  Chen,  A.P.  Albino, and  N.H.  Bander. 
1993.  Interleukin-10 production by  human  carcinoma  cell 
lines and its relationship to  interleukin-6 expression. Int. J. 
Cancer. 55:96-101. 
39.  Moore,  K.W., A.  O'Garra, R.  de Waal Male@t, P.  Vieira, 
and T.R. Mosmann. 1993.  lnterleukin-10. Annu. Rev. Immu- 
noI. 11:165-190. 
40. Matthes, T.,  F.C. Werner, H.  Tang,  X. Zhang, V. Kindler, 
and R.H. Zubler. 1993.  Cytokine mRNA expression during 
an in vitro response of human B lymphocytes: kinetics of B 
cell tumor necrosis factor alpha, interleukin (IL)6,  IL-10, and 
transforming growth factor beta 1 mlKNAs.J. Exp. Med.  178: 
521-528. 
41.  Rivas, J.M., and S.E. Ullrich. 1992.  Systemic suppression of 
delayed-type hypersensitivity by supematants from UV-irra- 
diated  keratinocytes.  An  essential  role  for  keratinocyte- 
derived IL-10.J. Immunol.  149:3865-3871. 
42. de Waal Male@t, R., J. Haanen, H. Spits, M.G. Roncarolo, 
A. te Velde, C. Figdor, K. Johnson,  R.  Kastelein, H. Yssel, 
and J. de Vries. 1991.  Interleukin 10 (IL-10) and viral IL-10 
strongly reduce antigen-specific human  T  cell proliferation 
by diminishing the antigen-presenting capacity of monocytes 
via downregulation of class II major histocompatibility com- 
plex expression.J. Exp. Med.  174:915-924. 
43. Ding, L., P.S. Linsley, L.Y. Huang, IK.N. Germain, and E.M. 
Shevach. 1993.  IL-10 inhibits macrophage costimulatory ac- 
tivity by selectively inhibiting the  up-regulation of B7  ex- 
pression. J. Immunol.  151 : 1224-1234. 
44.  Ferrara, J.L., and HJ.  Deeg.  1991.  Graft-versus-host disease 
[see comments]. N. Engl.J. Med.  324:667-674. 
45. Howard, M., and A.O'Garra.  1992.  Biological properties of 
interleukin 10. Immunol.  Today. 13:198-200. 
46. Lehmann, A.K., A. Halstensen, S. Somes, O. Rokke, and A. 
Waage. 1995. High levels ofinterleukin 10 in serum are asso- 
ciated with fatality in meningococcal disease.  Infect. Immun. 
63:2109-2112. 
47. Cortes, J.E., M.  Talpaz, F. Cabanillas, J.F. Seymour, and R. 
Kurzrock.  1995.  Serum levels of interleukin-10 in patients 
with  diffuse  large cell lymphoma: lack of correlation with 
prognosis. Blood. 85:2516-2520. 
48. Durez,  P., D. Abramowicz, C. Gerard, M.M. Van, Z. Am- 
raoui, C. Dubois, O. Leo, T. Velu, and M. Goldman. 1993. 
In vivo induction ofinterleukin 10 by anti-CD3 monoclonal 
antibody or bacterial lipopolysaccharide: differential modula- 
tion by cyclosporin A.J. Exp. Med.  177:551-555. 
49.  Suwa, S.,  and H.  Friesen. 1969.  Biosynthesis of human pla- 
cental proteins and human placental lactogen (HPL) in vitro. 
II. Dynamic studies of normal term placentas. Endocrinology. 
85:1037-1045. 
50. Buster, J.E.,  and J.A. Simrn.  1989.  Placental hormones,  hor- 
monal preparation for and  control of parturition, and  hor- 
monal diagnosis of pregnancy. In Endocrinology. LJ. DeGroot, 
editor. W.B. Saunders Company, Philadelphia. 3:2043-2073. 
51. Damsky, C.H., C. Librach, K.H. Lim, M.L. Fitzgerald, M.T. 
McMaster,  M.  Janatpour,  Y.  Zhou,  S.K.  Logan,  and  SJ. 
Fisher. 1994.  Integrin switching regulates normal trophoblast 
invasion. Development (Camb.).  120:3657-3666. 
52. Wegmann,  T.G.,  H.  Lin, L. Guilbert, and T.R.  Mosmann. 
1993. Bidirectional cytokine interactions in the maternal-fetal 
relationship: is  successful  pregnancy  a  TH2  phenomenon? 
Immunol.  Today. 14:353-356. 
53.  Fiorentino, D.F.,  M.W.  Bond,  and  T.R.  Mosmann.  1989. 
Two types of mouse T  helper cell. IV. Th2  clones secrete a 
factor  that  inhibits cytokine production  by  Thl  clones. J. 
Exp. Med.  170:2081-2095. 
54. Lin, H.,  T.R.  Mosmann,  L.  Guilbert, S.  Tuntipopipat, and 
T.G.  Wegmann.  1993.  Synthesis of T  helper 2-type cyto- 
kines at the  maternal-fetal interface. J.  Immunol.  151:4562- 
4573. 
55. Delassus,  S.,  G.C.  Coutinho,  C.  Saucier, S. Darche, and P. 
Kourilsky. 1994.  Differential cytokine expression in maternal 
blood and placenta during murine gestation.J. Immunol.  152: 
2411-2420. 
56. Roberts,  R.M., J.C.  Cross,  C.E.  Farin,  P.W.  Farin,  K.K. 
Kramer, H. Francis, C. Librach, and S.J. Fisher. 1991.  Tro- 
phoblast  interferons.  In  Growth  Factors in  Reproduction. 
547  Roth et al. D.W. Schombergs. Springer-Verlag, New York. 235-245. 
57.  Cadet, P., P.L. Rady, S.K. Tyring, R.B. Yandell, and T.K. 
Hughes.  1995.  Interleukin-10 messenger ribonucleic acid in 
human placenta: implications of a role for interleukin-10 in 
fetal allograft protection. Am.J.  Obstet. Gynecol. 173:25-29. 
58.  Heyborne, K.D., J.A. McGregor, G. Henry, S.S. Witkin, and 
J.S. Abrams. 1994.  Interleukin-10 in amniotic fluid at midtri- 
mester: immune activation and suppression in relation to fetal 
growth. Am. J.  Obstet. Gynecol. 171:55-59. 
59. Kuhn,  R., J.  Lohler,  D.  Rennick,  K.  Rajewsky,  and  W. 
Muller. 1993.  Interleukin-10-deficient mice develop chronic 
enterocolitis [see comments]. Cell. 75:263-274. 
60.  HiI1,J.A., K. Polgar, and D.J. Anderson. 1995. T-helper 1-type 
immunity to trophoblast in women with recurrent spontane- 
ous abortion [see comments].J.  Am.  Med. Assoc. 273:1933- 
1936. 
548  Placental Interleukin 10 Is Immunosuppressive 